-+ 0.00%
-+ 0.00%
-+ 0.00%

Bio-Thera Announces NMPA Approval of BAT2506, the First Golimumab Biosimilar Approved in China

Barchart·11/06/2026 06:00:00
Listen to the news

GUANGZHOU, China, Nov. 6, 2026 /PRNewswire/ -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, today announced that the National Medical Products Administration (NMPA) has approved its marketing authorization for BAT2506, a golimumab biosimilar.  This approval marks the first golimumab biosimilar approved in China.  BAT2506 will be marketed under the name 阿舒立® (ASHULI) and is approved by NMPA for the following indications: rheumatoid arthritis and ankylosing spondylitis.

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.